Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for refractory chronic cancer pain
NCT04666623Phase 2Withdrawn
- Sponsor
- University Hospital Basel
- Start
- Nov 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of esketamine in cancer pain, sponsored by University Hospital Basel. Primary endpoint: Numeric Pain Rating Scale at 4 weeks. Planned start Nov 2020; status: withdrawn.
02
Drugs
esketamine
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT04666623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04666623.